Skip to main content

Table 1 Descriptive statistics among all adult hospitalizations and bivariable analysis by aortic stenosis treatment modality among cancer patientsa

From: TAVR and cancer: machine learning-augmented propensity score mortality and cost analysis in over 30 million patients

Variables

Sample

Treatment

P-value

N = 30,195,722

MM (n = 4,640,563 [99.60%])

TAVR (n = 9318 [0.20%])

SAVR (n = 8852 [0.19%])

TAVR versus MM

TAVR vs SAVR

Demographics, no. (%)

 Age, mean (SD)

68.70 (14.30)

68.67 (14.31)

81.00 (7.93)

71.52 (9.35)

< 0.001

< 0.001

 Female

15,254,879 (50.52)

(50.54)

(40.2)

(32.61)

< 0.001

< 0.001

 Race, nonwhite

7,132,230 (23.62)

(23.65)

(10.00)

(10.97)

< 0.001

0.349

 Insurance, non-private

23,380,548 (77.43)

(77.4)

(93.23)

(79.23)

< 0.001

< 0.001

Medical history

 Diabetes

6247,495 (20.69)

(20.68)

(26.02)

(20.20)

< 0.001

< 0.001

 Hypertension

19,790,276 (65.54)

(65.49)

(88.13)

(81.14)

< 0.001

< 0.001

 Hyperlipidemia

11,869,938 (39.31)

(39.25)

(69.29)

(70.20)

< 0.001

0.546

 Congestive heart failure

1,926,487 (6.38)

(6.33)

(34.3)

(12.95)

< 0.001

< 0.001

 Smoking

332,153 (1.10)

(1.10)

(0.37)

(1.17)

< 0.001

0.005

 Depression

3,895,248 (12.90)

(12.91)

(7.6)

(9.43)

< 0.001

0.046

 Cirrhosis

742,815 (2.46)

(2.47)

(1.53)

(0.56)

0.009

0.004

 CKD 3–5

4,055,285 (13.43)

(13.4)

(24.54)

(11.55)

< 0.001

< 0.001

Outcomes, median (range)

 Mortality, no. (%)

1,201,790 (3.98)

(3.99)

(1.43)

(3.24)

< 0.001

< 0.001

 Length of stay, days

5.46 (6.34)

5.45 (6.34)

4.59 (4.56)

9.10 (7.09)

< 0.001

< 0.001

 Cost, dollars

60,612.22 (87,774.68)

60,002.30 (86,913.86)

210,106.90 (110,707.70)

219,202.30 (179,519.90)

< 0.001

0.065

  1. aMM medical management, TAVR transcatheter aortic valve replacement, SAVR surgical aortic valve replacement, bold = statistically significant, CKD chronic kidney disease